NASDAQ · DERM
Journey Medical Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for DERM: Nov 11, 2026
Journey Medical Corporation Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.03. The reported EPS for the same quarter last year was $-0.09.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.03 | $0.02 | $-0.08 | 2 |
| Dec 2026 | $-0.02 | $0.08 | $-0.12 | 2 |
| Mar 2027 | $0.08 | $0.08 | $0.08 | 1 |
| Jun 2027 | $0.15 | $0.15 | $0.15 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · The Motley Fool · MarketBeat- Zacks · Oct 23, 5:47 AM EDTKorro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?Korro Bio, Inc. (KRRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Zacks · Sep 21, 12:02 PM EDTAre Options Traders Betting on a Big Move in Journey Medical Stock?Investors need to pay close attention to DERM stock based on the movements in the options market lately.
- Zacks · Aug 25, 11:20 AM EDTELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
- RTTNews · Aug 20, 2:51 PM EDTTop Biotech Gainers: DERM Advances On Emrosi Growth, IOVA Revenue Climbs 66%, CAI Raises Guidance(RTTNews) – Today's top gainers in the biotech space include Journey Medical, following strong Emrosi sales and continued progress toward profitability; Iovance Biotherapeutics, after reporting record second-quarter revenue driven by Amtagvi; Caris Life Sciences, after raising it
- RTTNews · Aug 20, 11:59 AM EDTJourney Medical Reports 23% Q2 Revenue Growth; Emrosi Sales Drive Progress Toward Profitability(RTTNews) – Journey Medical Corporation (DERM), a commercial-stage pharmaceutical company focused on dermatological treatments, reported financial results for the second quarter ended June 30, 2026, highlighting continued commercial momentum for Emrosi and progress toward profita
- RTTNews · Aug 19, 9:16 PM EDTLongeveron Appoints Jhaveri As CFO Ahead Of Phase 2b Data; Stock Up(RTTNews) – Longeveron Inc. (LGVN), a clinical-stage biotech company focused on developing cellular therapies for rare paediatric and chronic age-related diseases, on Wednesday announced the appointment of Nirav Jhaveri as Chief Financial Officer (CFO).
- The Motley Fool · Aug 19, 5:58 PM EDTJourney Medical (DERM) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 12, 7:04 PM EDTJourney Medical Q2 Earnings Call HighlightsJourney Medical (NASDAQ:DERM) reported higher second-quarter revenue and a sharply narrower net loss as sales of its rosacea treatment EMROSI continued to grow, supported by rising prescription volume, broader prescriber adoption and improving payer reimbursement. Total revenue
- Zacks · Aug 12, 6:30 PM EDTHere's What Key Metrics Tell Us About Journey Medical (DERM) Q2 EarningsThe headline numbers for Journey Medical (DERM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- Zacks · Aug 12, 5:40 PM EDTJourney Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue EstimatesJourney Medical (DERM) delivered earnings and revenue surprises of 0.00% and -1.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 10, 9:10 AM EDTHeron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue EstimatesHeron Therapeutics (HRTX) delivered earnings and revenue surprises of -50.00% and -11.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 7:10 PM EDTArdelyx (ARDX) Reports Q2 Loss, Lags Revenue EstimatesArdelyx (ARDX) delivered earnings and revenue surprises of -40.00% and -2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Journey Medical Corporation from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.